Adverse effects of fenfluramine in treatment refractory schizophrenia. 1989

B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
Department of Psychology, University of California, Los Angeles.

Fenfluramine was administered to eight severely ill schizophrenic patients as an adjunct to neuroleptic drugs in a double-blind, multiple baseline design. A significant adverse effect of fenfluramine on psychopathology was detected through nurses' ratings, target symptom scales, the Brief Psychiatric Rating Scale, and time-sampled behavioral observations. Clinical deterioration was correlated with fenfluramine-induced reductions in blood serotonin levels and persisted beyond the point of discontinuation of fenfluramine.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005277 Fenfluramine A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release. Fintepla,Fenfluramine Hydrochloride,Fenfluramine Hydrochloride, (+-)-Isomer,Fenfluramine Hydrochloride, R-Isomer,Fenfluramine, (+-)-Isomer,Fenfluramine, R-Isomer,Isomeride,Pondimin,Fenfluramine Hydrochloride, R Isomer,Fenfluramine, R Isomer,Hydrochloride, Fenfluramine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
June 2000, Journal of clinical psychopharmacology,
B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
September 1988, Journal of autism and developmental disorders,
B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
September 1966, British medical journal,
B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
June 1990, Journal of clinical psychopharmacology,
B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
January 1999, Psychopharmacology,
B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
January 1975, The Ulster medical journal,
B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
March 2004, Progress in neuro-psychopharmacology & biological psychiatry,
B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
March 2004, Dialogues in clinical neuroscience,
B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
June 1995, L'Encephale,
B D Marshall, and S M Glynn, and K K Midha, and J W Hubbard, and L L Bowen, and L Banzett, and J Mintz, and R P Liberman
March 2005, Current opinion in psychiatry,
Copied contents to your clipboard!